272788-00-8 Usage
Description
R-VENLAFAXINE-DI-P-TOLUOYL-D-TARTRATE SALT is a derivative of (-)-Venlafaxine, which is a potent inhibitor of neuronal monoamine reuptake. This white solid compound is known for its ability to modulate the reuptake of neurotransmitters in the brain, thereby playing a significant role in the treatment of various psychiatric disorders.
Uses
Used in Pharmaceutical Industry:
R-VENLAFAXINE-DI-P-TOLUOYL-D-TARTRATE SALT is used as an active pharmaceutical ingredient for the treatment of major depressive disorder, generalized anxiety disorder, and other related psychiatric conditions. Its mechanism of action involves inhibiting the reuptake of serotonin and norepinephrine, which helps to improve mood, reduce anxiety, and alleviate other symptoms associated with these disorders.
Used in Research and Development:
In the field of neuroscience and pharmaceutical research, R-VENLAFAXINE-DI-P-TOLUOYL-D-TARTRATE SALT serves as a valuable compound for studying the effects of monoamine reuptake inhibition on brain function and behavior. It can be used to develop new drugs with improved efficacy and safety profiles, as well as to better understand the underlying mechanisms of psychiatric disorders and their treatment.
Used in Drug Delivery Systems:
Similar to gallotannin, R-VENLAFAXINE-DI-P-TOLUOYL-D-TARTRATE SALT can also be incorporated into novel drug delivery systems to enhance its bioavailability, delivery, and therapeutic outcomes. These systems may include various organic and metallic nanoparticles, liposomes, or other advanced formulations designed to improve the compound's pharmacokinetic properties and target specificity.
Check Digit Verification of cas no
The CAS Registry Mumber 272788-00-8 includes 9 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 6 digits, 2,7,2,7,8 and 8 respectively; the second part has 2 digits, 0 and 0 respectively.
Calculate Digit Verification of CAS Registry Number 272788-00:
(8*2)+(7*7)+(6*2)+(5*7)+(4*8)+(3*8)+(2*0)+(1*0)=168
168 % 10 = 8
So 272788-00-8 is a valid CAS Registry Number.
InChI:InChI=1/C20H18O8.C17H27NO2/c1-11-3-7-13(8-4-11)19(25)27-15(17(21)22)16(18(23)24)28-20(26)14-9-5-12(2)6-10-14;1-18(2)13-16(17(19)11-5-4-6-12-17)14-7-9-15(20-3)10-8-14/h3-10,15-16H,1-2H3,(H,21,22)(H,23,24);7-10,16,19H,4-6,11-13H2,1-3H3/t15-,16-;16-/m00/s1
272788-00-8Relevant articles and documents
Efficient resolution of venlafaxine and mechanism study via X-ray crystallography
Liu, Zhi-Jin,Liu, Han,Chen, Xuan-Wen,Lin, Min,Hu, Yu,Tuo, Xun,Yuan, Zhong-Yi,Sun, Xiao-Xia
, p. 268 - 274 (2018/02/19)
Numbers of resolving factors were investigated to improve resolution of venlafaxine 1. An effective resolving agent, O,O′-di-p-toluoyl-(R, R)-tartaric acid 2, was screened using similar method of ‘Dutch resolution’ from tartaric acid derivatives. The resolution efficiency was up to 88.4%, when the ratio of rac-1 and 2 was 1:0.8 in THF with little water (10:1?v/v). Enantiomerically pure venlafaxine was prepared with 99.1% ee in 82.2% yield. The chiral resolution mechanism was first explained through X-ray crystallographic study. One diastereomeric salt with well solubility forms a columnar supramolecular structure as the acidic salt (R)-1·2, while the other diastereomeric salt with less solubility forms a multilayered sandwich supramolecular structure by enantio-differentiation self-assembly as the neutral salt 2(S)-1·2. The water molecules play a key role in the optical resolution, as indicated by the special structures of the diastereomeric salts.
SOLID FORMS COMPRISING (-) O-DESMETHYLVENLAFAXINE AND USES THEREOF
-
Page/Page column 63, (2008/12/08)
Solid forms comprising a compound useful in the treatment, prevention and management of various conditions and diseases are provided herein. In particular, the invention provides solid forms comprising (-)-O-desmethylvenlafaxine, including salts thereof, having utility for the treatment, prevention and management of conditions and disorders including, but not limited to, affective disorders such as depression, bipolar and manic disorders, attention deficit disorder, attention deficit disorder with hyperactivity, Parkinson's disease, epilepsy, cerebral function disorders, obesity and weight gain, incontinence, dementia and related disorders.
